Challenges and Advantages in the Development of Cyclic Peptide Inhibitors of KRAS
mybcs
Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]